top of page
The
Promise of
Interleukin-2
Therapy.
4 - 7 Sept. 2024
For autoimmune and inflammatory diseases, allergy, transplantation and cancer
Centre international de Conférences Sorbonne Université
4 place Jussieu
75005 - Paris, France
*To submit before 15th June 2024
Confirmed Speakers
(by alphabetical order)
Christoph Binder, Pierre Ellul, Ron Germain, Jonathan Kipnis, David Klatzmann, Zhanguo Li, Adrian Liston, Ziad Mallat, Diane Mathis, Thomas Malek, Alexander Marson, Marc Martinez Llordella, Suman Mitra, Janie Robert, Aleksander Rudensky, Jamie Spangler, Shimon Sakaguchi, Qizhi Tang, Lucy Walker, Benjamin Youngblood, Jonathan Zalevsky
Confirmed speakers
Saturday 16th
8.30 am
Session VII
IL-2 and Treg cell therapies
Chair : M. Sadelain
- Lessons from CAR T cell in Cancer
M. Sadelain
- Current status of unmodified Treg therapy trials
Q. Tang UCSF
- CAR-Tregs
S. Boissel, TxCell
- Orthologs
2-3 talks from abstracts (including IL-2 engineered Tregs : ILTOO)
Session VII - Novel IL-2s (Chair: D Klatzmann)
1.Nektar (N…) (also covering IL2 and cancer)
2.Celgene (N…)
3.Roche (N…)
4.ILTOO (J Mariau)
5.2-3 talks from abstracts
Saturday 7th
9.00 am
Session IX
IL-2 in cancer therapy
Chair: Abbul Abbas
- Understanding and exploiting IL-2 activity in tissue microenvironments - Suman Mitra
Talks from abstract
11.00 - 11.30 am
Coffee Break
11.30 am
Session X
IL-2: the pharma perspective
Chair: George Tsokos, Abul Abbas, David Klatzmann
1. Nektar: Update on Rezpegaldesleukin Development as a Potential Treatment For Autoimmune Diseases Including Atopic Dermatitis - Jonathan Zalevsky 20’
2. BMS: IL-2/CD25 fusion - 20’
3. ILTOO: low dose native IL-2: from PoC to market - 20’
4. Round Table: What's next?
Talks from abstracts
1.30 pm
End of the meeting
Schedule Sat. 7th
bottom of page